ATARA Biotherapeutics (ATRA) Misses Q2 EPS by 2c

ATARA Biotherapeutics (NASDAQ: ATRA) reported Q2 EPS of ($0.91), $0.02 worse than the analyst estimate of ($0.89). Revenue for the quarter came in at $3.87 million versus the consensus estimate of $3.84 million.

For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30
• Vislink Technologies Inc. (VISL) Misses Q2 EPS by 7c